Compare EVTL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | IVVD |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 201.9M |
| IPO Year | 2021 | 2021 |
| Metric | EVTL | IVVD |
|---|---|---|
| Price | $0.78 | $0.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $12.70 | $8.75 |
| AVG Volume (30 Days) | ★ 9.0M | 3.6M |
| Earning Date | 03-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.74 | $0.53 |
| 52 Week High | $7.35 | $3.07 |
| Indicator | EVTL | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 28.04 | 63.56 |
| Support Level | N/A | $0.69 |
| Resistance Level | $1.42 | $1.01 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 6.40 | 75.07 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.